Mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
Non-small cell lung cancer (NSCLC) makes up the majority of lung cancers, which remains the leading cause of cancer mortality worldwide. NSCLC with mutant epidermal growth factor receptor (EGFR) is currently treated with tyrosine kinase inhibitors (TKIs). TKIs have proven effective in improving...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_US |
| Published: |
2019
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/2144/38589 https://orcid.org/0000-0002-0269-286X |